Endotronix
Endotronix develops the FDA-approved Cordella Pulmonary Artery Sensor System, an implantable MEMS-based device for remote hemodynamic monitoring of NYHA Class III heart failure patients. Acquired by Edwards Lifesciences in August 2024, it now operates as a wholly owned subsidiary.
- Company typePrivate
- Founded2017
- HeadquartersLisle, United States
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
Endotronix firmographics
Firmographics- Name
- Endotronix
- Legal name
- Endotronix, Inc.
- Website
- https://endotronix.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Acquired
- Headcount range
- 101–250 employees
- Short description
- Endotronix develops the FDA-approved Cordella Pulmonary Artery Sensor System, an implantable MEMS-based device for remote hemodynamic monitoring of NYHA Class III heart failure patients. Acquired by Edwards Lifesciences in August 2024, it now operates as a wholly owned subsidiary.
- Ownership category
- akta.pro rank
Endotronix industry classification
Industry- Product category
- Implantable Cardiac Hemodynamic Monitoring
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345), Surgical and Medical Instrument Manufacturing (339112)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Hemodynamic Monitoring & Cardiac Diagnostics (Cath Lab, FFR/IVUS/OCT) (HLAHAFAI)
- akta.pro secondary industries
- Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation) (HLAHAFAL), Cardiometabolic RPM & Chronic Disease Management (diabetes, hypertension, CHF, obesity) (HLALAFAA), Medical-Grade Device Connectivity & Device Management (MDM) (HLACAFAG)
Keywords
Where Endotronix is headquartered
LocationHeadquarters
- HQ city
- Lisle
- HQ country
- United States
- HQ region
- North America
Offices3 records
Markets served
Endotronix business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Others
Revenue model
- Cordella PA Sensor Implant: One-time sale of implantable pulmonary artery pressure sensor for heart failure patients. The sensor is implanted during a catheterization procedure and provides long-term pressure monitoring. Revenue recognized upon device implantation.
- Remote Patient Monitoring Services: Ongoing remote monitoring services supported by Medicare reimbursement codes including remote monitoring of wireless pulmonary artery pressure sensor and principal/chronic care management (P/CCM). Clinicians bill for clinically necessary services that improve patient monitoring and care coordination.
- Cordella HF System Platform: System includes patient reader, docking station, and cloud platform for data transmission and clinical review. May involve subscription or per-patient pricing for healthcare provider access to the management platform.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Per patient encounter | Medicare reimbursement codes support remote PA pressure monitoring and chronic care management |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels6 records
Endotronix product offering
Product offeringCore offering
Endotronix develops and commercializes the Cordella Pulmonary Artery Sensor System, an FDA-approved implantable medical device that continuously measures, records, and transmits pulmonary artery pressure data from NYHA Class III heart failure patients at home. The system pairs the implantable MEMS-based sensor with a handheld patient reader and a cloud-connected heart failure management platform (myCordella) that integrates vital signs, symptoms, and trend data to enable clinician-directed proactive care and remote medication optimization.
Product overview
Endotronix offers a single unified product—the Cordella Heart Failure System—for remote hemodynamic monitoring of heart failure patients. The system comprises three core components: the FDA-approved Cordella PA Sensor (an implantable MEMS-based pulmonary artery pressure sensor), the Cordella Delivery System (for sensor implantation), and the Cordella Patient Reader/Hub (handheld device for daily patient readings). These are integrated into a comprehensive patient management platform that includes the myCordella Hub tablet application for vital sign collection (blood pressure, weight, oxygen, pulse, symptoms) and secure clinician communication. The system is designed for NYHA Class III heart failure patients and enables proactive, PA pressure-guided management to reduce hospitalizations and improve outcomes.
Differentiator
Problem solved
Functional benefit
Brands
- Cordella: FDA-approved Pulmonary Artery Sensor and Heart Failure System for NYHA Class III heart failure patients, enabling remote hemodynamic monitoring
- myCordella
Products and services
- Cordella Pulmonary Artery Sensor System FDA-approved implantable pulmonary artery pressure sensor system for NYHA Class III heart failure patients, comprising an implanted MEMS-based sensor, a handheld patient reader, and a cloud-based HF management platform that allows clinicians to monitor patients at home and guide treatment decisions.
- CordellaCares Patient Access Program
Quantifiable outcome
- 73% reduction in HF hospitalization rate before and after Cordella use at 12 months
- +10 more outcomes
Companies that use Endotronix
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles2 records
Endotronix technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration1 record
Feature4 records
Endotronix partnerships and signals
Strategic signalScale indicators14 records
Expansion highlights5 records
Endotronix competitors and assessment
Company assessmentDirect peers
- Abbott: Abbott's CardioMEMS HF System is the direct, FDA-approved, commercially entrenched competitor to Cordella — an implantable PA pressure sensor for NYHA Class III heart failure patients supported by the CHAMPION trial. CardioMEMS defines the incumbent standard Cordella must displace in heart failure clinics.
Emerging players
- Vectorious Medical Technologies: Israel-based developer of the V-LAP, a second-generation left atrial pressure (LAP) sensor implant for heart failure management. Competes head-to-head with Cordella in the wireless implantable hemodynamic monitoring category, with overlapping customer base of heart failure specialists.
- Bodyport: Developer of a non-invasive cardiac scale for at-home hemodynamic monitoring in heart failure patients. Competes for the same NYHA Class III patient and reimbursement dollars as Cordella, with a fundamentally different (non-implant) workflow that could constrain Cordella adoption if it gains traction.
- Sensydia: Non-invasive cardiac output and hemodynamic assessment technology. Targets the same heart failure patient and clinician audience as Cordella with a non-implant workflow, making it a long-tail substitute on the diagnostic-monitoring side of heart failure management.
- Eko Health: Digital stethoscope and AI-enabled cardiac auscultation company expanding into heart failure screening and remote cardiac monitoring. A partial-overlap emerging player that targets the same cardiologists and HF patients with non-invasive, lower-cost workflow alternatives to implantable hemodynamic sensors.
Broad incumbents
- Medtronic: Diversified medtech incumbent with a heart failure portfolio (including cardiac resynchronization, ICDs, and remote monitoring via CareLink). Competes for the same hospital budget, heart failure specialist relationships, and remote-monitoring reimbursement codes that Cordella targets.
- Boston Scientific: Large cardiovascular medtech with heart failure diagnostics and remote monitoring offerings (e.g., LATITUDE patient management system) and structural heart therapies. Overlaps with Cordella in serving advanced heart failure patients and the cardiology channel.
- Edwards Lifesciences: Structural heart and critical care medtech leader that acquired Endotronix in August 2024. The relevant comparison is at the parent-portfolio level — Edwards' own heart failure, transcatheter, and monitoring franchises share channels and customers with Cordella.
- GE HealthCare: Large imaging, monitoring, and diagnostics incumbent with a portfolio spanning cardiac diagnostics, hospital patient monitoring, and EMR/clinical workflow software. Overlaps with Cordella in hospital procurement, EMR integration, and cardiology department relationships.
- Philips: Global health technology incumbent in cardiac monitoring, connected care, and remote patient management. Overlaps with Cordella in hospital patient monitoring, RPM platforms, and the cardiology channel — and competes for telehealth/RPM budget allocations in heart failure programs.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Endotronix social profiles
Digital presenceEndotronix compliance and trust
Trust signalCompliance1 record
Endotronix financial estimates
Financial estimateRevenue estimate
Valuation estimate
Endotronix leadership team
Management profileNumber of profiles
Endotronix funding detail
Funding detailFunding overview
Funding rounds10 records
Investors12 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Endotronix M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Endotronix
What does Endotronix do?
Endotronix develops and commercializes the Cordella Pulmonary Artery Sensor System, an FDA-approved implantable medical device that continuously measures, records, and transmits pulmonary artery pressure data from NYHA Class III heart failure patients at home. The system pairs the implantable MEMS-based sensor with a handheld patient reader and a cloud-connected heart failure management platform (myCordella) that integrates vital signs, symptoms, and trend data to enable clinician-directed proactive care and remote medication optimization.
Is Endotronix a public or private company?
Endotronix is a private company. It is classified as corporate owned and is currently acquired.
When was Endotronix founded?
Endotronix was founded in 2017. It employs 101 to 250 people.
Where is Endotronix based?
Endotronix is headquartered in Lisle, United States, in the North America region.
How does Endotronix make money?
Three revenue lines are on record. Cordella PA Sensor Implant is the primary driver. The others are remote Patient Monitoring Services and cordella HF System Platform.
Who are Endotronix's main competitors?
Abbott is listed as a direct peer. Emerging players are Vectorious Medical Technologies, Bodyport, Sensydia and Eko Health. Broad incumbents are Medtronic, Boston Scientific, Edwards Lifesciences, GE HealthCare and Philips.
Does Endotronix have an API?
No public API is recorded for Endotronix.
What industry is Endotronix in?
Endotronix's product category is Implantable Cardiac Hemodynamic Monitoring. Its primary akta.pro industry code is HLAHAFAI, Hemodynamic Monitoring & Cardiac Diagnostics (Cath Lab, FFR/IVUS/OCT), with a secondary code of HLAHAFAL, Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation). Its NAICS code is 334510 and its SIC code is 3845.